ReviewLipids in health and disease2011
Emerging therapeutic strategies to enhance HDL function.
Review in Lipids in health and disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion.International journal of molecular sciences · 2022Article
- Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.Molecules (Basel, Switzerland) · 2018Review
- Waist Circumference Coupled with Either HDL-C or TG Can Be Used as a Diagnostic Marker for Metabolic Syndrome in Chinese Women with Polycystic Ovary Syndrome.International journal of endocrinology · 2018Article
- Anti-Atherosclerotic Action of Agmatine in ApoE-Knockout Mice.International journal of molecular sciences · 2017Article
- Review
- Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.Journal of lipid research · 2014Article
- Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.Journal of medicinal chemistry · 2014Review
- Article
- Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Expert review of cardiovascular therapy · 2013Review
- Cholesterol crystals and inflammation.Current rheumatology reports · 2013Review
- Treating cardiovascular atherosclerotic plaques with Tongmaijiangzhi (TMJZ) capsule.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2013Article
- Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.Disease markers · 2013Article
- Article
- Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity.Lipids in health and disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened new expectations in the treatment of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.